Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR Advocacy Staff Outline Victories, Challenges from a Busy Year

Thomas R. Collins  |  November 21, 2023

SAN DIEGO—During the past year, ACR advocacy staff and volunteer leaders have been working on a range of pressing rheumatology issues. In an advocacy update session at ACR Convergence 2023, panelists described progress in multiple areas, including access to care and workforce issues.

The presentations conveyed how full the ACR’s slate of advocacy efforts has been and how important it is for rheumatologists and rheumatology health professionals to become more involved in those efforts. The ACR’s advocacy efforts include several volunteer committees: the Government Affairs Committee, the primary advocacy committee that determines the ACR’s policy priorities; the Committee on Rheumatologic Care (CORC), which works on policies specifically related to the practice of rheumatology and provides resources for practices; CORC’s Insurance Subcommittee, which directly interacts with payers on behalf of the ACR and members of the College; the Affiliate Society Council, a group of representatives of state and local rheumatology societies that tracks what is happening legislatively at the state level; and RheumPAC, the ACR’s political action committee, which focuses on fundraising.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A Personal Touch

ACR staffers attended 120 Congressional meetings and sent 36 letters to Congress in the past year, said Lennie Shewmaker McDaniel, JD, the ACR’s director of congressional affairs. The ACR is smaller than the American Medical Association and other specialty societies and organizations, she said, but it can make more of an impact politically than organizations that don’t represent voters in legislators’ districts.

The ACR represents community practitioners, she noted, providers who may sponsor a local baseball team or have kids in the same schools or activities as children of the Congressional representatives the ACR is interacting with. “We actually represent human beings that they interface with in their communities,” she said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The policy priorities for 2023 included Medicare reimbursement, barriers to care access, the rheumatology workforce shortage, drug pricing, and telehealth and research funding, said Ms. McDaniel.

She encouraged ACR members to send letters to Congress about issues they feel are important, saying such contacts lay the groundwork for future ACR meetings with legislators. “All of this loosens the ground,” she said. “So don’t think your letters just go into some black box.”

She described an environment in Congress that makes it especially challenging to get legislation passed. For example, an ostensibly non-contentious appropriations bill in the House was held up when a small group of lawmakers wanted to include language to interfere with implementation of a law regarding the use of family planning benefits that had already been passed in Washington, D.C.

Page: 1 2 3 | Single Page
Share: 

Filed under:ACR ConvergenceLegislation & Advocacy Tagged with:ACR advocacyACR Convergence 2023

Related Articles

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

    October 17, 2017

    As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety

    March 1, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences